SFM
STOK icon

Sphera Funds Management’s Stoke Therapeutics STOK Stock Holding History

Sphera Funds Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-188,640
Closed -$1.74M – 95
2022
Q4 		$1.74M Buy
188,640
+31,440
+20% +$327K 0.37% 43
2022
Q3 		$2.02M Buy
+157,200
New +$2.51M 0.28% 55
2021
Q3 		– Sell
-233,135
Closed -$7.85M – 148
2021
Q2 		$7.85M Buy
233,135
+82,406
+55% +$2.91M 0.53% 54
2021
Q1 		$5.85M Buy
+150,729
New +$8.58M 0.45% 65
2020
Q2 		– Sell
-27,254
Closed -$624K – 107
2020
Q1 		$624K Sell
27,254
-229,126
-89% -$5.66M 0.08% 68
2019
Q4 		$7.26M Sell
256,380
-90,000
-26% -$2.26M 0.6% 36
2019
Q3 		$7.38M Sell
346,380
-4,564
-1% -$127K 1.14% 23
2019
Q2 		$9.72M Buy
+350,944
New +$9.42M 1.33% 18

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Sphera Funds Management's STOK Position: Q1 2023 in Review

Sphera Funds Management sold out of Stoke Therapeutics (STOK) in Q1 2023, closing a stake of 188,640 shares — an estimated $1.74M sold.

Sphera Funds Management first reported a position in STOK in Q2 2019 and held it in 8 quarters. The position peaked at $9.72M in Q2 2019. 96 funds tracked by Wall St. Rank hold STOK as of Q1 2023.

  • Sphera Funds Management reported no remaining Stoke Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Sphera Funds Management sold 188,640 Stoke Therapeutics shares in Q1 2023, an estimated $1.74M.
  • Sphera Funds Management first reported a position in Stoke Therapeutics in Q2 2019 and held it in 8 quarters.
  • Sphera Funds Management's Stoke Therapeutics position peaked at $9.72M in Q2 2019.
  • 96 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2023.

Based on Sphera Funds Management's 13F filing for Q1 2023, filed 15 May 2023.